Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


04.11.2019

1 Am J Epidemiol
1 Am J Pathol
6 Ann Surg Oncol
3 BMC Cancer
1 Br J Cancer
3 Breast Cancer
1 Breast Cancer (Auckl)
1 Breast Cancer Res
6 Breast Cancer Res Treat
2 Breast J
1 Cancer Cell
1 Cancer Chemother Pharmacol
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Cancer Res
1 Clin Breast Cancer
4 Clin Cancer Res
1 Eur J Surg Oncol
1 Int J Cancer
4 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Clin Oncol
4 J Natl Cancer Inst
2 J Surg Oncol
3 Lancet Oncol
1 Nature
2 NPJ Breast Cancer
1 Oncol Rep
3 PLoS One
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Epidemiol

  1. MADDEN JM, Leacy FP, Zgaga L, Bennett K, et al
    Fitting marginal structural and G-estimation models under complex treatment patterns: investigating the association between de novo vitamin D supplement use post breast cancer diagnosis and all-cause mortality using linked pharmacy claim and registry
    Am J Epidemiol. 2019 Nov 1. pii: 5602656. doi: 10.1093.
    PubMed     Text format     Abstract available


    Am J Pathol

  2. WU L, Awaji M, Saxena S, Varney ML, et al
    Interleukin17-CXCR2 axis facilitates breast cancer progression by up-regulating neutrophil recruitment.
    Am J Pathol. 2019 Oct 22. pii: S0002-9440(19)30768.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  3. SINGH P, Kuerer HM
    ASO Author Reflections: Neoadjuvant Radiotherapy Followed by Immediate Breast Reconstruction Represents a Novel Therapeutic Sequence for Breast Cancer.
    Ann Surg Oncol. 2019 Oct 28. pii: 10.1245/s10434-019-07975.
    PubMed     Text format    

  4. VAN STEENHOVEN JEC, van Dalen T
    ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2- Breast Cancer.
    Ann Surg Oncol. 2019 Oct 24. pii: 10.1245/s10434-019-07955.
    PubMed     Text format    

  5. SUN SX, Kuerer HM
    ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
    Ann Surg Oncol. 2019 Oct 25. pii: 10.1245/s10434-019-07943.
    PubMed     Text format    

  6. QIAO E, Yu X, Zhou L, Wang C, et al
    A Prospective Validation Cohort Study of a Prediction Model on Non-sentinel Lymph Node Involvement in Early Breast Cancer.
    Ann Surg Oncol. 2019 Oct 28. pii: 10.1245/s10434-019-07980.
    PubMed     Text format     Abstract available

  7. HUEMAN MT, Shriver CD, Ellsworth RE
    ASO Author Reflections: Mitigating Survival Disparities in African American Women with Breast Cancer within the US Military Healthcare System-The Impact of Equivalent Care.
    Ann Surg Oncol. 2019 Oct 28. pii: 10.1245/s10434-019-08007.
    PubMed     Text format    

  8. YI M, Lin H, Bedrosian I, Shen Y, et al
    Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
    Ann Surg Oncol. 2019 Oct 30. pii: 10.1245/s10434-019-07983.
    PubMed     Text format     Abstract available


    BMC Cancer

  9. ZHANG W, Yang S, Liu J, Bao L, et al
    Screening antiproliferative drug for breast cancer from bisbenzylisoquinoline alkaloid tetrandrine and fangchinoline derivatives by targeting BLM helicase.
    BMC Cancer. 2019;19:1009.
    PubMed     Text format     Abstract available

  10. GOOSSENS M, De Brabander I, De Greve J, Van Ongeval C, et al
    Flemish breast cancer screening programme: 15 years of key performance indicators (2002-2016).
    BMC Cancer. 2019;19:1012.
    PubMed     Text format     Abstract available

  11. HANAMURA T, Ohno K, Hokibara S, Murasawa H, et al
    Clinical significance of serum PSA in breast cancer patients.
    BMC Cancer. 2019;19:1021.
    PubMed     Text format     Abstract available


    Br J Cancer

  12. TANG M, Schaffer A, Kiely BE, Daniels B, et al
    Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
    Br J Cancer. 2019 Nov 1. pii: 10.1038/s41416-019-0612.
    PubMed     Text format     Abstract available


    Breast Cancer

  13. NISHIYAMA K, Taira N, Mizoo T, Kochi M, et al
    Influence of breast density on breast cancer risk: a case control study in Japanese women.
    Breast Cancer. 2019 Oct 24. pii: 10.1007/s12282-019-01018.
    PubMed     Text format     Abstract available

  14. YAMAUCHI C, Yoshimura M, Sekiguchi K, Hamamoto Y, et al
    The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition.
    Breast Cancer. 2019 Oct 28. pii: 10.1007/s12282-019-01019.
    PubMed     Text format     Abstract available

  15. CHRISTENSEN TD, Buhl ASK, Christensen IJ, Buhl IK, et al
    Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay.
    Breast Cancer. 2019 Oct 25. pii: 10.1007/s12282-019-01017.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  16. BOZDEMIR H, Aygin D
    The Study of Validity and Reliability of the SPOFIA Scale in Patients With Postoperative Breast Cancer.
    Breast Cancer (Auckl). 2019;13:1178223419883833.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  17. BRANDT KR, Scott CG, Miglioretti DL, Jensen MR, et al
    Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer.
    Breast Cancer Res. 2019;21:118.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  18. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05480.
    PubMed     Text format     Abstract available

  19. SRIDHAR S, Rajesh C, Jishnu PV, Jayaram P, et al
    Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Oct 29. pii: 10.1007/s10549-019-05477.
    PubMed     Text format     Abstract available

  20. SHIM EJ, Lee JW, Cho J, Jung HK, et al
    Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.
    Breast Cancer Res Treat. 2019 Oct 31. pii: 10.1007/s10549-019-05479.
    PubMed     Text format     Abstract available

  21. BATENBURG MCT, Gregorowitsch ML, Maarse W, Witkamp A, et al
    Patient-reported cosmetic satisfaction and the long-term association with quality of life in irradiated breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05470.
    PubMed     Text format     Abstract available

  22. ZHENG L, Li X, Gu Y, Lv X, et al
    Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
    Breast Cancer Res Treat. 2019 Oct 26. pii: 10.1007/s10549-019-05478.
    PubMed     Text format     Abstract available

  23. BEDNAREK R, Selmi A, Wojkowska D, Karolczak K, et al
    Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05471.
    PubMed     Text format     Abstract available


    Breast J

  24. ARSENE HENRY A, Amessis M, Kirova YM
    Helical Tomotherapy for patients with pectus excavatum treated for early-stage breast cancer.
    Breast J. 2019 Oct 24. doi: 10.1111/tbj.13671.
    PubMed     Text format    

  25. MACDONALD HR
    Managing breast cancer risk in transgender men and women: Emerging safety data and a need for more research.
    Breast J. 2019;25:1063-1065.
    PubMed     Text format    


    Cancer Cell

  26. QUEREDA V, Bayle S, Vena F, Frydman SM, et al
    Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  27. SENTURK M, Ercan F, Yalcin S
    The secondary metabolites produced by Lactobacillus plantarum downregulate BCL-2 and BUFFY genes on breast cancer cell line and model organism Drosophila melanogaster: molecular docking approach.
    Cancer Chemother Pharmacol. 2019 Oct 31. pii: 10.1007/s00280-019-03978.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  28. KINNUNEN PT, Murto MO, Artama M, Pukkala E, et al
    Anticoagulants and breast cancer survival, a nationwide cohort study.
    Cancer Epidemiol Biomarkers Prev. 2019 Oct 25. pii: 1055-9965.EPI-19-0147.
    PubMed     Text format     Abstract available

  29. WIESE D, Stroup AM, Crosbie A, Lynch SM, et al
    The Impact of Neighborhood Economic and Racial Inequalities on the Spatial Variation of Breast Cancer Survival in New Jersey.
    Cancer Epidemiol Biomarkers Prev. 2019 Oct 24. pii: 1055-9965.EPI-19-0416.
    PubMed     Text format     Abstract available


    Cancer Lett

  30. KIM JE, Kim BG, Jang Y, Kang S, et al
    The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.
    Cancer Lett. 2019 Oct 28. pii: S0304-3835(19)30542.
    PubMed     Text format     Abstract available


    Cancer Res

  31. BARBIE TU, Ritter JL, Zhu Z, Thai TC, et al
    Phosphorylation of RAB7 by TBK1/IKKepsilon Regulates Innate Immune Signaling in Triple Negative Breast Cancer.
    Cancer Res. 2019 Oct 29. pii: 0008-5472.CAN-19-1310.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  32. WU W, Zhong J, Chen J, Niu P, et al
    Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Clin Breast Cancer. 2019 Sep 3. pii: S1526-8209(19)30654.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  33. HAMMERL D, Massink MPG, Smid M, van Deurzen CHM, et al
    Clonality, antigen recognition and suppression of CD8+ T cells differentially affect prognosis of breast cancer subtypes.
    Clin Cancer Res. 2019 Oct 24. pii: 1078-0432.CCR-19-0285.
    PubMed     Text format     Abstract available

  34. WEDAM S, Fashoyin-Aje L, Bloomquist E, Tang S, et al
    FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2019 Oct 24. pii: 1078-0432.CCR-19-2580.
    PubMed     Text format     Abstract available

  35. DE ANGELIS C, Nagi C, Hoyt CC, Liu L, et al
    Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy.
    Clin Cancer Res. 2019 Oct 25. pii: 1078-0432.CCR-19-1402.
    PubMed     Text format     Abstract available

  36. RIMAWI MF, Niravath P, Wang T, Rexer BN, et al
    TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer.
    Clin Cancer Res. 2019 Oct 29. pii: 1078-0432.CCR-19-0851.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  37. SIMONS JM, Maaskant-Braat AJG, Luiten EJT, Leidenius MH, et al
    Reply to: Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer in patients with pre-treatment node-positive: Recommnendation to optimize the performance.
    Eur J Surg Oncol. 2019 Oct 22. pii: S0748-7983(19)30902.
    PubMed     Text format    


    Int J Cancer

  38. KATALINIC A, Eisemann N, Kraywinkel K, Noftz MR, et al
    Breast cancer incidence and mortality before and after implementation of the German mammography screening program.
    Int J Cancer. 2019 Nov 1. doi: 10.1002/ijc.32767.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  39. MIRANDA DEGRANDE FA, Hanna SA
    In Regard to Patel et al.
    Int J Radiat Oncol Biol Phys. 2019;104:221.
    PubMed     Text format    

  40. BELKACEMI Y, Majdoul S, Tsoutsou PP, Abouegylah M, et al
    Is Postoperative Breast Radiation Therapy Safe in Patients With Scleroderma?
    Int J Radiat Oncol Biol Phys. 2019;104:10-11.
    PubMed     Text format    

  41. PATEL AK, Ling DC, Beriwal S
    In Reply to Miranda Degrande and Hanna.
    Int J Radiat Oncol Biol Phys. 2019;104:221-222.
    PubMed     Text format    

  42. JAOUDE JA, de Azambuja E, Makki M, Tamim H, et al
    Post-Mastectomy Radiation Therapy in HER-2 Positive Breast Cancer Patients: Analysis of the HERA Trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 22. pii: S0360-3016(19)33904.
    PubMed     Text format     Abstract available


    J Biol Chem

  43. MISHRA J, Simonsen R, Kumar N
    Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
    J Biol Chem. 2019 Oct 25. pii: RA119.007758. doi: 10.1074/jbc.RA119.007758.
    PubMed     Text format     Abstract available


    J Clin Oncol

  44. SHARMA P, Barlow WE, Godwin AK, Parkes EE, et al
    Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    J Clin Oncol. 2019 Oct 28:JCO1900693. doi: 10.1200/JCO.19.00693.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  45. BARECHE Y, Buisseret L, Gruosso T, Girard E, et al
    Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609116. doi: 10.1093.
    PubMed     Text format     Abstract available

  46. BRAUNSTEIN LZ, Riaz N
    Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609117. doi: 10.1093.
    PubMed     Text format    

  47. HEY SP, Gyawali B, D'Andrea E, Kanagaraj M, et al
    A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises.
    J Natl Cancer Inst. 2019 Oct 25. pii: 5607300. doi: 10.1093.
    PubMed     Text format     Abstract available

  48. ANURAG M, Zhu M, Huang C, Vasaikar S, et al
    Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
    J Natl Cancer Inst. 2019 Oct 30. pii: 5610076. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Surg Oncol

  49. FAYANJU OM, Williamson HV
    Response to Letter to the Editor: "The impact of chemotherapy sequence on survival in node-positive invasive lobular carcinoma".
    J Surg Oncol. 2019;120:566.
    PubMed     Text format    

  50. ALTUNDAG K
    Patients with invasive lobular and ductal carcinoma or pleomorphic lobular carcinoma might increase pathologic complete response rate and lower mastectomy rates compared to classical lobular type.
    J Surg Oncol. 2019;120:565.
    PubMed     Text format    


    Lancet Oncol

  51. PARK YH, Kim TY, Kim GM, Kang SY, et al
    Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 tr
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30565.
    PubMed     Text format     Abstract available

  52. DAS M
    Promising radiotherapy classifier for early breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30720.
    PubMed     Text format    

  53. ROBERT M, Turner N
    Endocrine-based therapy versus chemotherapy in advanced breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30686.
    PubMed     Text format    


    Nature

  54. KISER B
    Psychedelic psychiatry, breast cancer, and a paean to the emperor penguin: Books in brief.
    Nature. 2019;574:175.
    PubMed     Text format    


    NPJ Breast Cancer

  55. PAUL D, Vukelja SJ, Ann Holmes F, Blum JL, et al
    Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
    NPJ Breast Cancer. 2019;5:36.
    PubMed     Text format     Abstract available

  56. HASAN MK, Widhopf GF 2nd, Zhang S, Lam SM, et al
    Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.
    NPJ Breast Cancer. 2019;5:35.
    PubMed     Text format     Abstract available


    Oncol Rep

  57. CUI Y, Fan Y, Zhao G, Zhang Q, et al
    Novel lncRNA PSMG3AS1 functions as a miR1433p sponge to increase the proliferation and migration of breast cancer cells.
    Oncol Rep. 2019 Oct 25. doi: 10.3892/or.2019.7390.
    PubMed     Text format     Abstract available


    PLoS One

  58. MENDONCA P, Horton A, Bauer D, Messeha S, et al
    The inhibitory effects of butein on cell proliferation and TNF-alpha-induced CCL2 release in racially different triple negative breast cancer cells.
    PLoS One. 2019;14:e0215269.
    PubMed     Text format     Abstract available

  59. MANDRIK O, Yaumenenka A, Herrero R, Jonker MF, et al
    Population preferences for breast cancer screening policies: Discrete choice experiment in Belarus.
    PLoS One. 2019;14:e0224667.
    PubMed     Text format     Abstract available

  60. SHAHRIYARI L, Abdel-Rahman M, Cebulla C
    BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBM15B and USP19.
    PLoS One. 2019;14:e0211507.
    PubMed     Text format     Abstract available


    Radiology

  61. SUMKIN JH, Berg WA, Carter GJ, Bandos AI, et al
    Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer.
    Radiology. 2019 Oct 29:190887. doi: 10.1148/radiol.2019190887.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: